MDxHealth is a leading molecular diagnostics company focused on the development and commercialization of advanced epigenetic tests for cancer assessment and personalized patient treatment. The company applies its patented DNA methylation platform and biomarkers to help address a large and growing unmet medical need for better cancer diagnosis and treatment information. Formerly known as OncoMethylome Sciences, MDxHealth is headquartered in Belgium with U.S. headquarters in Irvine, Calif. For more information, visit the company’s Web site at www.mdxhealth.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: